



Séminaire de Modèles Industriels 2014

21 février

9h15 – 10h15

- **IPSEN**

IPSEN est au départ un acronyme signifiant "Institut des produits de synthèse et d'extraction naturelle". Cet acronyme ne définit cependant plus exactement les activités actuelles du groupe, qui s'est largement diversifié. Ipsen est en réalité un prolongement des Laboratoires Beaufour, laboratoire pharmaceutique français créé en 1929 par le docteur Henri Beaufour, à Dreux. Ipsen est aujourd'hui encore un laboratoire en partie contrôlé par la famille Beaufour, 20e fortune de France avec 1 996 M€ en 2009.

10h30 – 11h30

- **Galapagos**

Galapagos is a clinical stage biotech company focused on developing novel medicines. Headquartered in Belgium, the Company employs around 800 people and reported 2012 revenues of €153 million. Galapagos' most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.

11h30 – 12h30

- **Valneva**

Valneva is a new European biotech company focusing on vaccines and antibodies, striving to become a leader in its field. It was created in 2013 through the merger between InterCell AG and Vivalis SA, combining two value propositions – antibody discovery and vaccines development and commercialization.

14h00 – 15h00

- **ISIS_Pharmaceuticals**

ISIS_Pharmaceuticals is the leading company in antisense drug discovery and development, exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class drugs. For example it has developed mimomersen.

15h00 – 16h30

- **OTSUKA**

Fondée le 10 août 1964, elle emploie environ 27 000 employés en 2010. En 2007, elle aurait vendu pour 2 milliards USD de médicaments.

17h00 – 18h00

- **LFB**

Le LFB et ses filiales sont un groupe biopharmaceutique qui développe, fabrique et commercialise des médicaments dérivés du plasma et des biomédicaments indiqués dans la prise en charge de pathologies graves et souvent rares dans des domaines thérapeutiques majeurs : l'immunologie, les soins intensifs et l'hémostase ainsi que le développement d'anticorps monoclonaux et de protéines de nouvelle génération issues des biotechnologies.

Le Groupe met en oeuvre une stratégie de croissance axée sur le développement de ses activités à l'international et sur la mise au point de thérapies innovantes.

26 février

14h00 – 15h00

- **Covance**

Covance is one of the world's largest and most comprehensive drug development services companies with more than 11,000 employees in 60 countries. Through its discovery, nonclinical, clinical and commercialization services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today. Covance has the people, processes, client service and global resource capabilities to respond to the toughest drug development challenges.

15h00 – 16h00

- **Patheon**

Patheon is the world's leading provider of contract drug development and manufacturing services. Through an integrated network of facilities across North America and Europe, we give global pharmaceutical, biotechnology and specialty pharmaceutical companies access to the expertise and resources to bring drug candidates from preclinical stages through clinical trials to commercial manufacturing

16h00 – 17h00

- **QIAGEN**

At the forefront of the molecular biology revolution, more than 500,000 customers worldwide are using QIAGEN Sample & Assay Technologies to achieve breakthroughs based on the building blocks of life - DNA, RNA and proteins. Doctors are diagnosing diseases more precisely and quickly to guide treatment decisions. Scientists are conquering new frontiers in the understanding of life - and translating that knowledge into better medications. And experts are safeguarding the public with molecular technologies for human identification, veterinary testing and food safety.